Patents by Inventor Matthieu Sollogoub

Matthieu Sollogoub has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Capped cyclodextrin-hydrophobic moiety conjugate, cyclodextrin supramolecular polymer, and cyclodextrin-siRNA complex and method of synthesis thereof
    Patent number: 10947323
    Abstract: The invention relates to a capped cyclodextrin-hydrophobic moiety conjugate, to a supramolecular polymer formed of capped cyclodextrin-hydrophobic moiety conjugates according to the invention and to a siRNA-cyclodextrin complex comprising a supramolecular polymer according to the invention. The invention also relates to a method for manufacturing the capped cyclodextrin-hydrophobic moiety conjugate, the supramolecular polymer, the siRNA-cyclodextrin complex according to the invention. The capped cyclodextrin-hydrophobic moiety conjugate of the invention comprises a capped cyclodextrin group and at least one hydrophobic moiety bound by a first linker to one of the carbon atoms of the cap. The invention can be used for various applications in particular in the pharmaceutical field.
    Type: Grant
    Filed: September 5, 2016
    Date of Patent: March 16, 2021
    Assignees: Sorbonne Universite, Centre National De La Recherche Scientifique, Institut National De La Sante Et De La Recherche Medicale (INSERM), Assistance Publique—Hopitaux De Paris, Université De Paris
    Inventors: Matthieu Sollogoub, Vincent Calvez, Anne-Geneviève Marcelin, Laurent Bouteiller, Mickaël Menand, Pierre Evenou, Adélie Gothland, Dmitri Colesnic, Julien Rossignol
  • CAPPED CYCLODEXTRIN-HYDROPHOBIC MOIETY CONJUGATE, CYCLODEXTRIN SUPRAMOLECULAR POLYMER, AND CYCLODEXTRIN-siRNA COMPLEX AND METHOD OF SYNTHESIS THEREOF
    Publication number: 20200010576
    Abstract: The invention relates to a capped cyclodextrin-hydrophobic moiety conjugate, to a supramolecular polymer formed of capped cyclodextrin-hydrophobic moiety conjugates according to the invention and to a siRNA-cyclodextrin complex comprising a supramolecular polymer according to the invention. The invention also relates to a method for manufacturing the capped cyclodextrin-hydrophobic moiety conjugate, the supramolecular polymer, the siRNA-cyclodextrin complex according to the invention. The capped cyclodextrin-hydrophobic moiety conjugate of the invention comprises a capped cyclodextrin group and at least one hydrophobic moiety bound by a first linker to one of the carbon atoms of the cap. The invention can be used for various applications in particular in the pharmaceutical field.
    Type: Application
    Filed: September 5, 2016
    Publication date: January 9, 2020
    Applicants: Sorbonne Universite, Centre National De La Recherche Scientifique, Institut National De La Sante Et De La Recherche Medicale (INSERM), Assistance Publique - Hopitaux De Paris, Universite Paris Descartes
    Inventors: Matthieu SOLLOGOUB, Vincent CALVEZ, Anne-Geneviève MARCELIN, Laurent BOUTEILLER, Mickaël MENAND, Pierre EVENOU, Adélie GOTHLAND, Dmitri COLESNIC, Julien ROSSIGNOL
  • Nucleoside analogues for the treatment of a viral infection, and method for evaluating the sensitivity to said treatment
    Patent number: 9181294
    Abstract: The present invention describes the use of nucleoside analogs for the treatment of viral infections, in particular of an HIV infection, and also compositions comprising at least one of these analogs, and a method for evaluating the sensitivity to said treatment.
    Type: Grant
    Filed: October 23, 2012
    Date of Patent: November 10, 2015
    Assignee: Universite Pierre Et Marie Curie (Paris 6)
    Inventors: Vincent Calvez, Anne-Genevieve Marcelin, Cathia Soulie, Melanie Etheve-Quelquejeu, Matthieu Sollogoub
  • NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF A VIRAL INFECTION, AND METHOD FOR EVALUATING THE SENSITIVITY TO SAID TREATMENT
    Publication number: 20140323425
    Abstract: The present invention describes the use of nucleoside analogues for the treatment of viral infections, in particular of an HIV infection, and also compositions comprising at least one of these analogues, and a method for evaluating the sensitivity to said treatment.
    Type: Application
    Filed: October 23, 2012
    Publication date: October 30, 2014
    Applicant: Universite Pierre et Marie Curie (Paris 6)
    Inventors: Vincent Calvez, Anne-Genevieve Marcellin, Cathia Soulie, Melanie Eheve-Quelquejeu, Matthieu Sollogoub
  • IMINO-SUGAR C-GLYCOSIDES, PREPARATION AND USE THEREOF
    Publication number: 20140296288
    Abstract: The present disclosure relates to iminosugar derivatives and processes for the preparation thereof. The disclosed compounds have glycosidase inhibiting properties, and are useful in the treatment of various diseases, such as type 2 diabetes, neurodegenerative diseases or lysosomal storage disorders. The present disclosure also relates to pharmaceutical compositions containing the disclosed compounds and to their use as biochemical tools.
    Type: Application
    Filed: July 19, 2012
    Publication date: October 2, 2014
    Applicants: UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), DORPHAN S.A., CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Matthieu Sollogoub, Yves Bleriot, Giuseppe Prencipe, Nicolas Auberger